December 2010

Contents

Editorial

• Volume 11 Number 11/12 November/December 2010

Conference reports

• 10th International Congress on Drug Therapy in HIV Infection, 7-–11 November 2010, Glasgow

• Virological findings from the SARA trial ofboosted protease inhibitor monotherapy

• Nevirapine exposure was not associated with hypersensitivity in patients from Malawi

• Estimating the number of people in a country or region with HIV who are undiagnosed and in need of ART

• Highpreterm delivery rates associated with initiation of HAART during pregnancy at a London clinic

• Minority M184V variants detected in women after receiving 3TC/FTC and LPV/r-containing regimens in pregnancy

• The Antiretroviral Pregnancy Registry reports no increased rate of birth defects with atazanavir exposure

• Pharmacokinetics of lopinavir/ritonavir incombination with rifampicin based TB treatment in children

• Efavirenz versus nevirapine based first linetreatment in a South African cohort

• GSK572: 24-week results in treatment-naive and raltegravir-experienced patients

• Consensus guidelines recommend routine use of genotypic tropism testing: new focus on maraviroc as a switching option (2010)

• UK studies on bone health: increasedfracture rates reported in HIV-positive people

• Muscle weakness or pain analysed as possible raltegravir side effect

• Adding maraviroc does not boost CD4s inrandomised trial

• Switch to twice-daily unboosted atazanavir outdoes switch to once-daily dose

• Small but higher rates of AIDS and non-AIDS complications with uncontrolled HIV despite CD4s over 350

• 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, 4-–6 November 2010, London

• Bio-Alcamid associated with unacceptable risk of complications: no longer recommended as a treatment for facial lipoatrophy

• First International Workshop on HIV and Ageing, 4-–5 October 2010, Baltimore

• T-cell senescence linked to KS in peoplewith good HIV control

• Higher risk of potential drug-drug interactions in HIV patients over 60

• Age raises fracture risk more in HIV-positive people

Antiretrovirals

• Once-daily raltegravir fails to demonstrate non-inferiority compared to twice-dailydosing in phase 3 treatment naive study

• FDA safety updates to antiretroviral labels

• Update to US saquinavir label

Treatment access

• Shortfall in funding for the Global Fund

• FDA approval of generic ARVs

• Europe! HANDS OFF OUR MEDICINE

• DNP+ president uses 5ml of blood to meet Carla Bruni-Sarkozy

• Medicines Patent Pool: first research funder announced

Paediatric care

• Initiating nevirapine with fixed dose combination “mini-pills” in Zambia

Side effects

• FDA approves tesamorelin for reduction of central fat accumulation

HIV prevention and transmission

• Pre-exposure prophylaxis (PrEP) with tenofovir/FTC reduces sexual transmission of HIV between men at high risk: results from the iPrEx study

Basic science and immunology

• Berlin man remains free of detectable HIV 3.5 years after CCR5-negative stem celltransplant

• Natural immunity to HIV infection

• Scant embers of infection can reignite viralreplication

• Evidence for sporadic low-level HIV replication on ART

• Plumbing HIV pathogenesis in the gut

• Genetic analyses reveal key mechanism of HIV control

BHIVA news

• HIV: an agenda for action

On the web

• Conference reports and online abstracts

• Online journal access

• Community resources and publications

PDFs

• Volume 11 Number 11/12 November/December 2010 PDF